EP0724573A1 - Pyrimidinones utilisees comme antiarthritiques et anti-inflammatoires - Google Patents

Pyrimidinones utilisees comme antiarthritiques et anti-inflammatoires

Info

Publication number
EP0724573A1
EP0724573A1 EP94928624A EP94928624A EP0724573A1 EP 0724573 A1 EP0724573 A1 EP 0724573A1 EP 94928624 A EP94928624 A EP 94928624A EP 94928624 A EP94928624 A EP 94928624A EP 0724573 A1 EP0724573 A1 EP 0724573A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
methyl
oxo
alkyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94928624A
Other languages
German (de)
English (en)
Inventor
Richard Allen Nugent
Stephen T. Schlachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of EP0724573A1 publication Critical patent/EP0724573A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Definitions

  • the present invention is directed toward pyrimidinones and their pharmaceutically acceptable salts which are characterized by (Formula I) which are useful as anti-inflammatories and antiarthritic agents.
  • the present compounds are useful in humans and lower animals as a safe and effective treatment of chronic inflammatory diseases. These diseases include periodontal disease, rheumatoid arthritis, osteoarthritis, neuritis, bursitis, pneumoconioses, Crohn's disease, chronic inflammatory bowel disease, chronic asthma, atherosclerosis, multiple sclerosis, and sarcoidosis.
  • US Patent 4,746,654 discloses bisphosphonates useful as anti-inflammatory agents
  • Australian Patent A-51534/85 discloses bisphosphonates useful in treating abnormal calcium and phosphorous metabolism and useful in treating arthritis
  • US Patent 3,683,080 discloses polyphosphonates; in particular, diphosphonates useful in inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
  • European Patent Application 0 168 262 discloses an intermediate pyrimidine compound, Formula Vila which is similar to the subject compound except that the corresponding R 2 is only hydrogen or a lower alkyl. The compounds are described to be useful for treating hypertension and cerebrovascular disease.
  • the present invention is pyrimidinones or its pharmaceutically acceptable salts which are structurally represented by Formula I
  • R 2 is a) (CH 2 ) n -Y and i) where n is 1 then Y is C r C 6 alkoxy, morpholinyl, piperdinyl, pyrrolidinyl, phenoxy, phenylthio, phenylsulfonyl, phenylsulfinyl, -NHC(O)-C 1 -C 6 carboxylic acid, N 3 , NH 2 , diethylamino, hydrogen (provided R 4 is benzyloxy), halogen (provided R 3 is a C j -Cg alkyl) or CH("EWG") 2 where "EWG" is an electron withdrawing group each individually selected from the group consisting of CO 2 R or
  • R 3 is hydrogen or C j -C 8 alkyl
  • R 4 is hydrogen, hydroxyl, C j -C 8 alkyl, alkoxy, benzyloxy or phenoxy
  • R 5 is hydrogen, halogen, C j -C 8 alkyl, C j -C 8 alkoxy, phenoxy, C j -C 8 alkylthio, thiophenyl, NH 2 , Aryl (except that R 5 is other than phenyl when R 4 and Y are both hydrogen) or Heteroaryl;
  • R 6 is H, C j -C 8 alkyl, benzyl, phenyl, phenyl substituted with one to five F, Cl, Br, I, NO 2 , OCH 3 or C r C 4 alkyl;
  • R 7 is H, C j -C alkyl, benzyl, phenyl, phenyl substituted with one to five F, Cl, Br, I, NO 2 , OCH g or C j -C ⁇ alkyl, or where both R 7 's are taken together to form a CH 2 - CH , CH 2 -CH 2 -CH 2 or CH 2 -C(CH 3 ) 2 -CH 2 whereby a heterocyclic ring containing the bonded P atom and the two O atoms is formed.
  • the present invention comprises the use of these compounds in humans and lower animals as a safe and effective treatment of chronic inflammatory diseases.
  • the invention is a method for treating inflammation by administering to a patient (animals, including humans) in need of such treatment an anti-inflammatory effective amount of a compound of Formula I.
  • routes of administration include oral, intramuscular, intravenous, transdermal, intra-articular, subcutaneous, or intraperitoneal.
  • An effective amount is an amount whereby the symptoms of inflammation or arthritis such as pain and discomfort are relieved or reduced or mobility of the affected area is increased.
  • a typical dosage is about 0.001 mg to 1.0 gram with dose determined by the particular mode of administration, use and frequency of administration.
  • the present invention comprises pyrimidinones and their pharmaceutically acceptable salts which are characterized by (Formula I, above) and which are useful as anti-inflammatories and anti-arthritic agents. These compounds are particularly useful in the treatment of arthritis and its associated symptoms such as inflammation and excessive bone growth or remodelling.
  • Formula I the variable designations are further defined as follows.
  • C-C j defines the number of carbon atoms present from the integer "i" to the integer "j” inclusive.
  • C j -C 8 alkyl refers to alkyl of 1-3 carbon atoms, inclusive, or methyl, ethyl, propyl, and isopropyl.
  • C j -C 8 alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, and isomeric forms thereof.
  • aAryl means phenyl or naphthyl.
  • Heteroaryl means morpholinyl, piperazinyl, piperidinyl, imidazolidinyl, pyrazolidinyl, isoxazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl.
  • halogen includes fluoro, chloro, bromo and iodo.
  • Pharmaceutically acceptable salts means salts useful for administering the compounds of this invention or useful forms the compounds may take in vitro or in vivo and include potassium, sodium, hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, mesylate, maleate, malonate, succinate, tartrate, citric acid and the like. These salts may be in hydrated form.
  • pyrimidinones and derivatives (Formula I) useful as anti-inflammatories and antiarthritics are prepared as shown in Examples 1-35 and in Table 1, below.
  • the Formula I compounds of this invention have been tested in a Delayed Type Hypersensitivity Granuloma Assay (DTH GRA) model for inflammation.
  • DTH GRA Delayed Type Hypersensitivity Granuloma Assay
  • mice have a DTH granuloma (DTH GRA) lesion induced by subcutaneously implanting a mBSA-soaked filter which is excised after nine days.
  • DTH GRA DTH granuloma
  • Compounds are administered to the mice to determine their effect on the lesions. The results are recorded as percent inhibition. The larger the inhibition, the more effective the compound. Inhibition of 10 to 20% is considered to indicate anti- granuloma activity. Greater than 30% inhibition is good activity.
  • the DTH GRA data obtained from the compounds of Formula 1 are shown in the Table 2, below. The compounds are scored as having anti-inflammatory activity at 10-20% inhibition and good activity at greater than 30% inhibition.
  • Example 2 Made by the same method of Example 2 were Examples 3-6, whose compounds are identified below.
  • EXAMPLE 3 4(3H)-Pyrimidinone, 3-methyl-6-phenyl-2-[(phenylthio)methyl]-
  • EXAMPLE 4 Phosphonic acid, [2-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl) ethylidene]bis-, tetraethyl ester
  • R 3 is methyl
  • R 4 is hydrogen
  • R 5 is phenyl
  • R 2 is -CH 2 -CH-(PO(OEt) 2 ) 2 , mp 86-88°C.
  • EXAMPLE 5 Propanedioic acid, [(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)methyl]-, diethyl ester
  • R 3 is methyl
  • R 4 is hydrogen
  • R 5 is phenyl
  • R 2 is -CH 2 -CH-(CO 2 Et) 2 , mp 102-103°C.
  • EXAMPLE 6 2-Pyrimidinepropanoicacid,.alpha.-(diethoxyphosphinyl)-l,6- dihydro-1- methyl-6-oxo-4-phenyl-, ethyl ester
  • R 3 is methyl
  • R 4 is hydrogen
  • R 5 is phenyl
  • R 2 is -CH 2 -CH(CO 2 Et)(PO(OEt) 2 ), mp 119°C.
  • Example 7 Made by the same method of Example 7, the title compound was prepared, mp 133-134°C.
  • Example 7 Made by the same method of Example 7, the title compound was prepared, mp 84-85°C.
  • EXAMPLE 12 4(3H)-Pyrimidinone, 2-(aziodomethyl)-3-methyl-6-phenyl- 4(3H)-Pyrimidinone, 2-(iodomethyl)-3-methyl-6-phenyl- (4.06 g, 12.4 mmol) was treated with sodium azide (1.62 g, 24.9 mmol) and acetonitrile (25 ml) and stirred at 22°C for 60 hours then concentrated in vacuo. The residue was dissolved in methylene chloride, washed with saturated NaHCO 3 , 3x IM NaHSO 3 , saturated NaCl, dried with MgSO 4 , and concentrated in vacuo (40%), mp 111-112°C.
  • EXAMPLE 15 Butanoic acid, 4-[[(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl) methyl] amino]-4-oxo- 4(3H)-Pyrimidinone, 2-(aminomethyl)-3-methyl-6-phenyl- (304 mg, 1.41 mmol) dissolved in chloroform (5 ml) was treated with succinic anhydride (141 mg, 1.41 mmol) then heated to reflux for 1 hour. The resultant solid was filtered, washed with chloroform and dried: 0.377 g, (1.20 mmol, 85%), mp 200-201°C.
  • Example 15 In a similar to Example 15 manner the title compound was prepared: from glutaric anhydride (62%), mp 181-182°C.
  • Benzenesulfinic acid, sodium salt (0.346 g, 2.1 mmol) was slurried in toluene (5 ml), then treated with 4(3H)-Pyrimidinone, 2-(iodomethyl)-3-methyl-6-phenyl- (0.517 g, 1.6 mmol) and heated to 70°C for 20 hours. The reaction was cooled to room temperature and most of the solvent was removed in vacuo. The residue was dissolved in methylene chloride, washed thrice with saturated NaHCO g and IM NaHSO g , dried with MgSO 4 , and concentrated in vacuo.
  • title compound was prepared from glutaric anhydride (26%), mp 170-171°C.
  • EXAMPLE 22 Phosphonic acid, [(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyl)cyclopropylidene]bis-,tetraethyl ester
  • EXAMPLE 25 Propanedioic acid, [2-(l,6-dihydro-l-methyl-6-oxo-4-phenyl-2- pyrimidinyDethyl]-, bis(l,l-dimethylethyl) ester 4(3H)-Pyrimidmone, 2,3-dimethyl-6-phenyl (0.744 g, 3.72 mmol) was dissolved in THF (37 ml), cooled to -78°C, then treated with lithium bis(trimethylsilyl)amide (4.1 ml, 4.1 mmol).
  • the ester (22.10 g, 0.113 mol) was dissolved in THF (5 ml) and added slowly to a -78°C solution of LiHMDS (1 M in THF, 230 ml, 0.230 mol). After stirring for 45 minutes, benzoyl chloride (13.1 ml, 0.113 mol) was added and the reaction warmed to room temperature for 45 minutes. It was quenched with 1 N HC1, extracted thrice with methyl t-butyl ether, dried with MgSO 4 , and stripped: 45.68 g (0.153 mol).
  • the crude material, acetamidine hydrochloride (28.95 g, 0.306 mol), and 25% sodium methoxide/methanol (77 ml, 0.336 mol) were combined and heated to reflux for 36 hours. It was cooled, diluted with water, and pH adjusted to 7 with concentrated HC1. The precipitate was collected, washed with cold ether, and air dried: 20.45 g (70.00 mmol, 62%), mp 168°C.
  • the pyrimidinone (5.84 g, 20.0 mmol), K g CO g (3.20 g, 23 mmol), and methyl iodide (3.7 ml, 60 mmol) were heated in refluxing methanol (50 ml) overnight. The reaction was cooled and seeded. The precipitate was collected, washed with water and dried in the oven: 5.052 g (16.49 mmol, 82%), mp 118-119°C.
  • EXAMPLE 28 Phosphonic acid, [3-(l,6-dihydro-5-hydroxy-l-methyl-6-oxo-4- phenyl-2-pyrimidinyl)propylidene]bis-, tetraethyl ester Phosphonic acid, [3-[l,6-dihydro-l-methyl-6-oxo-4-phenyl-5-(phenylmethoxy)-2- pyrimidinyl]propylidene]bis-, tetraethyl ester (1.60 g, 2.64 mmol) in ethanol (50 ml) was treated with 10% Pd/C (320 mg) and ammonium formate (4.00 g), then heated to reflux for 2 hours.
  • the catalyst was removed by filtering through Celite and stripped. The residue was dissolved in methylene chloride, filtered through a short pad of silica gel and the pad was washed well with acetone. After concentration, the crude material was recrystallized from methyl t-butyl ether: 884 mg (1.71 mmol, 65%), mp 138-139°C.
  • Hydrogen chloride gas (2.0 g, 55 mmol) was slowly bubbled into acetonitrile (7.5 ml).
  • EXAMPLE 31 4(3H)-Pyrimidinone,2,3-dimethyl-6-phenylthio- Sodium hydride (0.36 g, 7.5 mmol) slurried in dimethyl formamide (25 ml) was treated with thiophenol (0.73 ml, 7.12 mmol) and 6-chloro-2,3-dimethyl-4(3H)- pyrimidinone (1.13 g, 7.13 mmol). The mixture was stirred at 22°C for 24 hours then diluted with H 2 O (70 ml).
  • EXAMPLE 32 4(3H)-Pyrimidinone, 2,3-dimethyl-6-piperidinyl 4(3H)-Pyrimidinone, 6-chloro-2,3-dimethyl- (0.778 g, 4.90 mmol) was slurried in piperidine (15 ml) and the solution was heated to reflux for 1 hour, then at 60°C for 18 hours. The reaction mixture was filtered through Celite and concentrated in vacuo. The residue was dissolved in methylene chloride and washed with 6% NaHCO 3 , 2 x H 2 O, then dried with MgSO 4 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés s'avérant utiles dans le traitement de l'inflammation, dont la structure correspond à la formule (I), ou leurs sels pharmacocompatibles, où R2 représente a) (CH¿2?)n-Y i) où n est 1, donc Y est C1-C6 alkoxy, morpholinyle, piperdinyle, pyrrolidinyle, phénoxy, phénylthio, phénylsulfonyle, phénylsulfinyle, -NHC(O)-C1-C6 acide carboxylique, N3, NH2, diéthylamino, hydrogène (à condition que R?4¿ soit benzyloxy), halogène (à condition que R3 soit C¿1?-C6 alkyle) ou CH('EWG')2 où 'EWG' est un groupe de retrait d'électrons dont chacun est choisi individuellement dans le groupe consistant en CO2R?6¿ ou PO(OR7)2, ou bien ii) n est 2, donc Y est CH('EWG')2, ou bien b) une oléfine terminale substituée par i) un aryle ou un hétéroaryle, ii) hydroxyle et un C1-C6 alkyle, phényle ou (CH2)m-CO2R6 où m est 1 ou 3, ou bien c) C¿3?-C6 cycloalkyle (facultativement substitué par halogène, (PO(OC2H5)2)2 ou CN; R?3¿ représente hydrogène ou C¿1?-C6 alkyle; R?4¿ représente hydrogène, hydroxyle, C¿1?-C6 alkyle, alkoxy, benzyloxy ou phénoxy; R?5¿ représente hydrogène, halogène, C¿1?-C6 alkyle, C1-C6 alkoxy, phénoxy, C1-C6 alkylthio, thiophényle, NH2, Aryle (sauf si R?5¿ diffère de phényle lorsque R4 et Y sont tous deux hydrogène) ou Hétéroaryle; R6 représente H, C¿1?-C6 alkyle, benzyle, phényle, phényle substitué par un à cinq F, C1, Br, I, NO2, OCH3 ou C1-C4 alkyle; et R?7¿ représente H, C¿1?-C6 alkyle, benzyle, phényle, phényle substitué par un à cinq F, C1, Br, I, NO2, OCH3 ou C1-C4 alkyle, ou si les deux R?7¿' forment ensemble un CH¿2?-CH2, CH2-CH2-CH2 ou CH2-C(CH3)2-CH2, un cycle hétérocyclique contenant l'atome P lié et les deux atomes de O est formé. Ces composés s'avèrent utiles comme antiarthritiques et anti-inflammatoires.
EP94928624A 1993-10-20 1994-09-21 Pyrimidinones utilisees comme antiarthritiques et anti-inflammatoires Withdrawn EP0724573A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13907893A 1993-10-20 1993-10-20
US139078 1993-10-20
US16167693A 1993-12-03 1993-12-03
US161676 1993-12-03
PCT/US1994/010571 WO1995011235A1 (fr) 1993-10-20 1994-09-21 Pyrimidinones utilisees comme antiarthritiques et anti-inflammatoires

Publications (1)

Publication Number Publication Date
EP0724573A1 true EP0724573A1 (fr) 1996-08-07

Family

ID=26836841

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94928624A Withdrawn EP0724573A1 (fr) 1993-10-20 1994-09-21 Pyrimidinones utilisees comme antiarthritiques et anti-inflammatoires

Country Status (4)

Country Link
EP (1) EP0724573A1 (fr)
JP (1) JPH09504010A (fr)
AU (1) AU7798994A (fr)
WO (1) WO1995011235A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025596A2 (fr) * 1996-12-12 1998-06-18 Pharmacia & Upjohn Company Methode de traitement de la sclerose en plaques
EP1483247B1 (fr) 2002-03-13 2009-06-24 Euro-Celtique S.A. Pyrimidines substituees par aryle et utilisation associee
MXPA04011074A (es) * 2002-05-09 2005-06-08 Cytokinetics Inc Compuestos de pirimidinona, composiciones y metodos.
EP1509507A4 (fr) * 2002-05-23 2006-09-13 Merck & Co Inc Inhibiteurs de kinesine mitotique
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
CA2547209A1 (fr) 2003-12-19 2005-07-07 Merck & Co., Inc. Inhibiteurs de kinesines mitotiques
BRPI0516001A (pt) 2004-10-13 2008-08-19 Pharmacia & Upjohn Co Llc formas cristalinas de 3-[5-cloro-4-[(2, 4-difluorobenzil) óxi]-6-oxopirimidin-1(6h)-il]-n-(2-hidroxietil)-4-metilben zamida
GB201111705D0 (en) * 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9212147B2 (en) 2011-11-15 2015-12-15 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
MX2015000830A (es) 2012-07-18 2015-10-26 Sunshine Lake Pharma Co Ltd Derivados heterociclicos nitrogenosos y su aplicacion en farmacos.
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
UY35735A (es) 2013-09-16 2015-04-30 Bayer Pharma AG Trifluorometilpirimidinonas disustituidas y su uso
ES2663806T3 (es) 2013-12-19 2018-04-17 unshine Lake Pharma Co., Ltd. Derivados heterocíclicos nitrogenados y su aplicación en el tratamiento de la fibrosis tisular
WO2016113205A1 (fr) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Pentafluoréthylpyrimidinones substituées et leur utilisation
US20230219907A1 (en) * 2019-12-23 2023-07-13 Sitryx Therapeutics Limited Carboxy derivatives with antiinflamatory properties

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521622B1 (fr) * 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Esters de l'acide pyrazolopyrimidine et pyrimidinyl bisphosphonique comme anti-inflammatoires
US5298481A (en) * 1992-07-17 1994-03-29 Rohm And Haas Company 6-arylpyrimidines and herbicidal use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9511235A1 *

Also Published As

Publication number Publication date
JPH09504010A (ja) 1997-04-22
WO1995011235A1 (fr) 1995-04-27
AU7798994A (en) 1995-05-08

Similar Documents

Publication Publication Date Title
WO1995011235A1 (fr) Pyrimidinones utilisees comme antiarthritiques et anti-inflammatoires
JP3526575B2 (ja) ホスホン酸誘導体
US5635495A (en) Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
US5397774A (en) Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
US5273990A (en) Phosphono substituted tetrazole derivatives
US5550119A (en) Phosphono substituted tetrazole derivatives as ECE inhibitors
US6706698B2 (en) α-Substituted β-aminoethyl phosphonate derivatives
AU605340B2 (en) A process for the manufacture of novel unsaturated amino acid compounds
EP0660840B1 (fr) Derives de tetrazole a substitution phosphono
EP0654035B1 (fr) Acides et esters phosphonoacetiques en tant qu'agents anti-inflammatoires
US5175344A (en) Unsaturated amino acids
US20030114421A1 (en) Alpha-substituted beta-aminoethyl phosphonate derivatives
US20020111488A1 (en) Beta-substitued beta-aminoethyl phosphonate derivatives
US20050124581A1 (en) Alpha-substituted heteroarylalkyl phosphonate derivatives
US20050124586A1 (en) Alpha-substituted arylalkyl phosphonate derivatives
SI8811501A (sl) Postopek za pripravo novih nenasičenih spojin amino kislin
WO2004026242A2 (fr) Inhibiteurs de ketophosphonate substitue contre la proliferation d'une cellule tumorale

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960503

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 960503;SI PAYMENT 960503

RAX Requested extension states of the european patent have changed

Free format text: LT PAYMENT 960503;SI PAYMENT 960503

17Q First examination report despatched

Effective date: 19960724

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN COMPANY

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980911